Abstract 14346: Combined Cornell Voltage and Quantitative Assessment of Absolute Area Under ST Segment Predicts Cardiovascular Events in Japanese General Practice Population: J-HOP Study
Introduction: Both ECG-left ventricular hypertrophy diagnosed by Cornell voltage (CV-LVH) and the classic strain pattern or depression of ST segment have been accepted to be associated with adverse prognosis in clinical population. However, there are a few studies about the quantitative assessment of ST segment.
Hypothesis: We assessed the hypothesis whether the area under of ST segment (AUST) using computerized measurements as the degree of AUST is associated with cardiovascular events.
Methods: We analyzed 834 patients (mean age 63±11years, male 52%) performing ECG of 4310 patients recruited for the J-HOP study. The absolute AUST above or below isoelectric baseline was measured by computer in lead V5.
Results: After a mean follow up of 6.2 years, there were 58 cardiovascular events. The patients with CV-LVH were suffered more cardiovascular events than those without (Figure A). When we divided patients into quintiles based on AUST, cardiovascular events were significantly increased at the lowest quintile (≤0.084msec•mV) compared with any other groups (Figure B). The group with both CV-LVH and the lowest quintile of AUST had a highest risk of cardiovascular events among 3 groups (Figure C). Multivariate Cox analysis demonstrated that after adjustment for other potential predictors, the combination of CV-LVH and the lowest quintile of AUST had a significant predictor of cardiovascular events compared with those without both CV-LVH and the lowest quintile of AUST (Hazard ratio, 3.25; 95% confidence interval 1.41-7.51, P=0.006) .
Conclusions: The combination CV-LVH and absolute area of ST segment was a predictor of cardiovascular events in Japanese general practice population.
Author Disclosures: S. Hoshide: None. T. Kabutoya: None. Y. Imai: None. K. Eguchi: None. N. Jimba: None. T. Yoneyama: None. T. Yamauchi: None. T. Sawada: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI, Bayer Yakuhin Ltd., A &D Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., MOCHIDA PHARMACEUTICAL CO., LTD, EA pharma, Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Inc., Mitsubishi Tanabe Pharma Corporation., Medtronic Japan Co., Ltd.. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc, AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., TERUMO CORPORATION, Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., SANWA KAGAKU KENKYUSHO CO.,LTD., MSD K.K., Actelion Pharmaceuticals Japan, Abott Japan, OMRON HEALTHCARE Co., Ltd., Century Medical Inc., TOA EIYO LTD., MOCHIDA PHARMACEUTICAL CO., LTD, Sumitomo Dainippon Pharma Co., Ltd.. Honoraria; Significant; Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., OMRON HEALTHCARE Co., Ltd..
- © 2016 by American Heart Association, Inc.